Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 15/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.38 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.38 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368855 | 0.88 | CYP17A1 (0.61) | CYP17A1CYP1A2HTTRAB9ASMN1; SMN2 | |
| SCHEMBL367468 | 0.85 | CYP17A1 (0.53) | CYP17A1CYP1A2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL368300 | 0.83 | CYP17A1 (0.41) | CYP17A1CYP1A2HTTRAB9ASMN1; SMN2 | |
| SCHEMBL25975112 | 0.83 | CYP17A1 (0.74) | CYP17A1CYP1A2SCN9AHTTRAB9A | |
| SCHEMBL368955 | 0.81 | CYP17A1 (0.57) | CYP17A1CYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL15105539 | 0.81 | CYP17A1 (0.45) | CYP17A1CYP1A2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL25342346 | 0.80 | CYP17A1 (0.60) | CYP17A1CYP1A2SCN9AHTTRAB9A | |
| SCHEMBL359298 | 0.80 | CYP17A1 (0.60) | CYP17A1CYP1A2SCN9A | |
| SCHEMBL368885 | 0.79 | CYP17A1 (0.41) | CYP17A1CYP1A2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL368630 | 0.77 | CYP17A1 (0.42) | CYP17A1CYP1A2SLC2A1SLC2A3SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012064815-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064815-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | CYP3A7, CYP2C19, UGT2B17 | CYP17A1 45/4885CYP1A2 8/4885SCN9A 2334/4885 |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | CYP17A1 53/4885CYP1A2 9/4885SCN9A 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.